Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AdaptVac
Mpox And Newfound ‘Punching Power’ Are Bringing Bavarian Nordic Closer To $1bn Target
Bavarian Nordic managed to change its financial story in 2022 when its smallpox vaccine, Jynneos, became a critical tool in the global response to the mpox pandemic. CEO Paul Chaplin speaks to In Vivo about what this year holds in store.
Coronavirus Update: FDA Approves Pfizer/BioNTech's Comirnaty
The FDA granted an expected, though long-awaited, approval to the COVID-19 vaccine. Also, Korean regulators have begun a review of Russian vaccine CoviVac, while Bavarian Nordic has initiated a Phase II study of its vaccine booster candidate and received a commitment for up to DKK 800m from the Danish government.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.